Compare Dishman Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs LUPIN - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA LUPIN DISHMAN PHARMA/
LUPIN
 
P/E (TTM) x 25.1 47.5 52.9% View Chart
P/BV x 3.3 2.4 137.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   LUPIN
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
LUPIN
Mar-19
DISHMAN PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs374986 38.0%   
Low Rs129720 17.9%   
Sales per share (Unadj.) Rs197.8369.5 53.5%  
Earnings per share (Unadj.) Rs21.213.4 158.2%  
Cash flow per share (Unadj.) Rs34.737.4 92.9%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9303.7 59.2%  
Shares outstanding (eoy) m80.69452.49 17.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.3 55.1%   
Avg P/E ratio x11.963.6 18.6%  
P/CF ratio (eoy) x7.222.8 31.8%  
Price / Book Value ratio x1.42.8 49.8%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,306386,064 5.3%   
No. of employees `0000.817.7 4.7%   
Total wages/salary Rs m5,35531,513 17.0%   
Avg. sales/employee Rs Th19,252.79,453.8 203.6%   
Avg. wages/employee Rs Th6,459.51,782.0 362.5%   
Avg. net profit/employee Rs Th2,064.1343.0 601.8%   
INCOME DATA
Net Sales Rs m15,961167,182 9.5%  
Other income Rs m2653,640 7.3%   
Total revenues Rs m16,226170,822 9.5%   
Gross profit Rs m4,10328,822 14.2%  
Depreciation Rs m1,09110,850 10.1%   
Interest Rs m9443,078 30.7%   
Profit before tax Rs m2,33418,534 12.6%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m138 2.9%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m6249,017 6.9%   
Profit after tax Rs m1,7116,066 28.2%  
Gross profit margin %25.717.2 149.1%  
Effective tax rate %26.748.7 54.9%   
Net profit margin %10.73.6 295.5%  
BALANCE SHEET DATA
Current assets Rs m11,018138,536 8.0%   
Current liabilities Rs m9,51761,299 15.5%   
Net working cap to sales %9.446.2 20.4%  
Current ratio x1.22.3 51.2%  
Inventory Days Days11084 131.9%  
Debtors Days Days35112 31.0%  
Net fixed assets Rs m16,304127,516 12.8%   
Share capital Rs m161905 17.8%   
"Free" reserves Rs m12,907136,517 9.5%   
Net worth Rs m14,516137,422 10.6%   
Long term debt Rs m4,18966,417 6.3%   
Total assets Rs m29,805279,494 10.7%  
Interest coverage x3.57.0 49.4%   
Debt to equity ratio x0.30.5 59.7%  
Sales to assets ratio x0.50.6 89.5%   
Return on assets %8.93.3 272.3%  
Return on equity %11.84.4 267.1%  
Return on capital %17.58.9 196.8%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95259,414 8.3%   
Fx outflow Rs m69722,282 3.1%   
Net fx Rs m4,25537,132 11.5%   
CASH FLOW
From Operations Rs m2,78616,660 16.7%  
From Investments Rs m-1,529-32,825 4.7%  
From Financial Activity Rs m-9417,441 -12.6%  
Net Cashflow Rs m316-8,724 -3.6%  

Share Holding

Indian Promoters % 61.4 46.6 131.8%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 3.7 11.3 32.7%  
FIIs % 12.7 31.9 39.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.1 218.8%  
Shareholders   46,261 98,259 47.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - UNICHEM LAB COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS